Barrett Katz - 13 Jan 2023 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Medical Officer
Signature
/s/ Lara Meisner, Attorney-in-Fact for Barrett Katz
Issuer symbol
VRDN
Transactions as of
13 Jan 2023
Net transactions value
-$410,391
Form type
4
Filing time
18 Jan 2023, 16:58:22 UTC
Previous filing
11 Jan 2023
Next filing
10 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Options Exercise $95,505 +4,147 $23.03 4,147 13 Jan 2023 Direct
transaction VRDN Common Stock Sale $153,480 -4,147 -100% $37.01 0 13 Jan 2023 Direct F1
transaction VRDN Common Stock Options Exercise $572,365 +24,853 $23.03 24,853 17 Jan 2023 Direct
transaction VRDN Common Stock Sale $924,780 -24,853 -100% $37.21 0 17 Jan 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -4,147 -1.4% $0.000000 291,853 13 Jan 2023 Common Stock 4,147 $23.03 Direct F3
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -24,853 -8.5% $0.000000 267,000 17 Jan 2023 Common Stock 24,853 $23.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.05. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.58. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.